Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]

Core Viewpoint - The partnership between Beijing Economic-Technological Development Area and Shouyao Holdings aims to enhance the biopharmaceutical and health industry in Beijing Yizhuang through the establishment of a new headquarters at the BioPark, which will focus on drug research and industrialization [1][3]. Investment and Development - Shouyao Holdings will invest 787 million yuan (approximately 7.87 billion) to build a new drug research and industrialization base at BioPark, covering an area of about 38,000 square meters, expected to be completed by 2028 [3]. - The company has rapidly developed since its establishment in Beijing Yizhuang in 2019, focusing on innovative small molecule anti-tumor drug research, with a pipeline that includes key cancer indications such as non-small cell lung cancer and lymphoma [3]. Product Pipeline and Clinical Progress - Shouyao Holdings has made significant progress with its core products: the new drug application for SY-707 has been accepted; SY-3505 is the first third-generation ALK kinase inhibitor to enter clinical trials in China, with smooth progress in its pivotal Phase III clinical study; SY-5007 has completed key clinical trial participant enrollment and plans to initiate market application in the first half of this year, potentially becoming China's first commercialized RET inhibitor [3][4]. Strategic Shift and Future Goals - The company plans to transition from a research-focused model to a dual emphasis on research and commercialization, aiming for product sales next year and striving for profitability [4]. - The entry of Shouyao Holdings is expected to significantly boost the regional economy and promote high-quality development in the biopharmaceutical and health industry [4]. BioPark Development and International Collaboration - BioPark is accelerating the formation of an international pharmaceutical innovation cluster, with major investments from companies like Bayer, AstraZeneca, and Medtronic, indicating a strong trend towards international collaboration in the pharmaceutical sector [5]. - The "Implementation Plan for High-Quality Construction of the International Pharmaceutical Innovation Park (2025-2030)" outlines goals for BioPark, including the establishment of a talent hub and the completion of key functional areas by 2030, positioning it as a global center for pharmaceutical health innovation [5].

Group 1 - The A-share market experienced a slight adjustment with the pharmaceutical sector showing low opening fluctuations, while the Kexin Pharmaceutical Index ETF (588700) saw a minor rebound, currently down 0.11% with premium trading observed [1] - The National Medical Products Administration (NMPA) is implementing comprehensive reforms in drug regulation to enhance drug safety and support high-quality development in the pharmaceutical industry, as stated by Xu Jinghe, Deputy Director of NMPA [1] - Huayuan Securities reported that innovative drug companies are projected to achieve revenues of 47.53 billion yuan in 2024, marking a year-on-year growth of 68.4%, indicating strong momentum in the sector [1] Group 2 - Guoyuan Securities highlighted that Chinese innovative drugs are considered the highest quality assets globally, with the industry benefiting from a decade of development since the 2015 drug research policy reform [2] - The integration of high-quality resources, including skilled engineers and clinical resources, has led to recognition of the results by multinational corporations (MNCs), which is expected to accelerate MNCs' efforts in innovative drug business development [2] - The outlook for Chinese innovative drugs in international markets is optimistic, with the potential for significant growth in overseas licensing opportunities [2]

Meeting Guidelines - The company has established meeting guidelines to ensure the rights of all shareholders are protected during the shareholder meeting [1][2] - Only authorized personnel, including shareholders, their agents, directors, supervisors, senior management, and invited guests, are allowed to enter the meeting venue [1][2] - Shareholders must arrive 30 minutes before the meeting to complete registration and present identification [1][2] Shareholder Rights and Conduct - Shareholders and their agents have the right to speak, consult, and vote during the meeting, but must adhere to the rules to maintain order [2][3] - Any questions or speeches must be registered in advance and should be concise, limited to 5 minutes [2][3] - The meeting host has the authority to refuse or stop any disruptive behavior [2][3] Voting Procedures - Voting will be conducted through a named ballot system, where each share represents one vote [3] - Votes can be cast as "agree," "disagree," or "abstain," and improperly filled ballots will be considered abstentions [3] - The meeting will include both on-site and online voting, with results announced after the voting period [3] Meeting Agenda - The meeting is scheduled for May 20, 2025, at 10:00 AM in Beijing [5] - The agenda includes registration, reports from independent directors, shareholder speeches, and voting on various proposals [5][6] - Key proposals include the approval of the 2024 annual report and the board's work report [5][6] Financial Overview - The company reported a significant decrease in revenue for 2024, with total revenue of approximately 3.94 billion yuan, a decline of 24.61% compared to 2023 [27] - The net profit attributable to shareholders was approximately -211.94 million yuan, indicating a loss compared to previous years [27] Future Plans - The company plans to invest approximately 230 million yuan in research and development in 2025, an increase of 8.14% from 2024 [19][17] - The focus will be on advancing clinical trials for key products and expanding the drug pipeline [19][17] - The company aims to enhance its market strategies and strengthen its sales team to improve competitiveness [18][19]

首药控股（北京）股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 会议须知 为维护首药控股（北京）股份有限公司（以下简称"公司"）全体股东在 2024 年年度股东大会期间的合法权益，确保股东大会的正常秩序和议事效率， 根据《中华人民共和国公司法》《上市公司股东大会规则》及《首药控股（北 京）股份有限公司章程》《首药控股（北京）股份有限公司股东大会议事规则》 等的规定，特制定会议须知如下： 一、为确认出席大会的股东、股东代理人或其他出席人员的出席资格，会 议工作人员须对出席会议者的身份进行必要的核对，请给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，除 出席会议的股东及股东代理人、公司董事、监事、高级管理人员、见证律师及 董事会邀请的人士外，公司有权依法拒绝其他无关人员进入会场。 三、出席会议的股东及股东代理人须在会议召开前 30 分钟到达会议现场办 理签到手续，并请按规定出示身份证明（身份证或身份证明文件、法人股东的 营业执照或单位证明、相关授权文件、股东账户卡等），经验证后领取会议资 料，方可入席。会议开始后，由会议主持人宣布现场出席会议的股东人数及其 所持有表 ...

公司摊薄每股收益为-1.43元，在已披露的同业公司中排名第126，较去年同报告期摊薄每股收益减少 0.18元。 公司最新总资产周转率为0.00次，在已披露的同业公司中排名第128，较去年同期总资产周转率持平， 同比较去年同期下降9.30%。最新存货周转率为0.02次，在已披露的同业公司中排名第128，较去年同期 存货周转率减少0.07次，同比较去年同期下降74.29%。 2025年4月28日，首药控股(688197.SH)发布2024年年报。 公司营业总收入为394.20万元，在已披露的同业公司中排名第128，较去年同报告期营业总收入减少 128.71万元，同比较去年同期下降24.61%。归母净利润为-2.12亿元，在已披露的同业公司中排名第 114，较去年同报告期归母净利润减少2636.73万元。经营活动现金净流入为-1.97亿元，在已披露的同业 公司中排名第122，较去年同报告期经营活动现金净流入减少1720.13万元。 公司最新资产负债率为12.28%，较去年同期资产负债率增加4.08个百分点。 公司最新毛利率为98.96%，较去年同期毛利率增加1.08个百分点。最新ROE为-26.20%，在已披露的同 ...

证券代码：688197 证券简称：首药控股 公告编号：2025-008 首药控股（北京）股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 首药控股（北京）股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日 分别召开第二届董事会第八次会议和第二届监事会第七次会议，会议审议通过 了《关于使用暂时闲置募集资金进行现金管理的议案》，同意公司在确保不影响 募集资金投资项目进度、不影响公司正常生产经营及确保资金安全的情况下， 使用额度不超过 5 亿元（含本数）的闲置募集资金进行现金管理，购买安全性 高、流动性好的具有合法经营资格金融机构销售的保本型投资产品（包括但不 限于银行理财产品、券商理财产品及其他投资产品等），在上述额度范围内，资 金可循环滚动使用，使用期限自本次年度董事会审议通过之日起至下一年度董 事会召开之日止；同时同意授权公司董事长行使投资决策并签署相关法律文件， 包括但不限于：选择合资格机构、产品品种、明确投资金额、投资期限、签署 合同或协议、开立 ...

根据中国证监会《上市公司独立董事管理办法》《上海证券交易所科创板股 票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等的规定，首药控股（北京）股份有限公司（以下简称"公司"）董事会对在 任独立董事江骥、刘学、杨国杰的独立性自查情况进行评估，并出具如下专项意 见： 首药控股（北京）股份有限公司董事会 对独立董事独立性自查情况的专项报告 首药控股（北京）股份有限公司董事会 2025 年 4 月 24 日 经核查独立董事江骥、刘学、杨国杰的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》中对独立董事 独立性的相关要求。 ...

证券代码：688197 证券简称：首药控股 公告编号：2025-011 首药控股（北京）股份有限公司 关于与北京经济技术开发区管理委员会 签署《经济发展合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别提示： 1．本次项目投资资金来源为公司自有及自筹资金。鉴于该项目投资总额较 大，公司将密切关注信贷政策的变化及融资渠道的通畅程度，在控制整体资产 负债率的前提下，积极拓展融资渠道，统筹好未来经营现金流分布、外部直接 或间接资金筹措情况；同时，建设资金将依据项目实施计划和进度安排分批投 入使用，尽可能分摊集中投入的压力。经对公司流动性和营运资金需求进行评 估，并进行了相关压力测试后认为，公司财务及现金流风险相对安全、可控。 2．公司须通过招拍挂程序获得协议约定的项目宗地，可能存在竞买不成功 而无法在拟定地区取得建设用地的风险。此外，项目建设涉及办理项目备案、 环评审批、建设规划许可、施工许可等前置审批工作，尚需获得有关主管部门 批复。 3.项目拟投资金额、建设周期均为依据当前内部规划所做出的排期及测算， ...

中信建投证券股份有限公司 关于首药控股（北京）股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为首药控股（北京）股份有限公司（以下简称"首药控股"或"公司"）首次公 开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 规则适用指引第 1 号——规范运作》和《科创板上市公司持续监管办法（试行）》 等有关规定，对首药控股使用暂时闲置募集资金进行现金管理事项进行了审慎核 查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）"证监许可〔2022〕 258 号"文注册同意，经上海证券交易所《关于首药控股（北京）股份有限公司 人民币普通股股票科创板上市交易的通知》（自律监管决定书〔2022〕77 号）同 意，公司发行的人民币普通股股票在上海证券交易所科创板上市。公司首次公开 发行人民币普通股（A 股）3,718.00 万股，募集资 ...